Prostatic Acid Phosphatase (PAP), Serum
| Prostatic Acid Phosphatase (PAP), Serum | | | |
| Number | | 004747 |
| CPT | | 84066 |
| Related Information | | Prostate-Specific Antigen (PSA), Free:Total Ratio Prostate-Specific Antigen (PSA), Free:Total Ratio Reflex Prostate-Specific Antigen (PSA), Free:Total Ratio Reflex (Serial Monitor) |
| Synonyms | | Acid Phosphatase, Prostatic ; PAP |
| Special Instructions | | This test is not the same as Acid Phosphatase. Values obtained with different assays should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy. This procedure does not provide serial monitoring; it is intended for one-time use only. If serial monitoring is required, please use the serial monitoring number 480152. |
| Specimen | | Serum |
| Volume | | 0.5 mL |
| Minimum Volume | | 0.2 mL (Note: This volume does not allow for repeat testing.) |
| Container | | Red-top tube or gel-barrier tube; do not use acid phosphatase transport tube. |
| Collection | | If a red-top tube is used, transfer separated serum to a plastic transport tube. Specimen should be free of hemolysis and lipemia. |
| Storage Instructions | | Refrigerate |
| Causes for Rejection | | Plasma specimen |
| Reference Interval | | 0-3.5 ng/mL |
| Use | | An adjunct in the evaluation of possible prostatic malignancy and useful in monitoring therapeutic progress |
| Methodology | | Immunochemiluminometric assay (ICMA) |
| Additional Information | | Prostatic acid phosphatase has been used as a tumor marker ever since the observation by Gutman in 19381 that elevated levels of this enzyme are found in patients with metastatic prostate cancer. PAP determination in conjunction with PSA measurements is useful in assessing the prognosis of prostate cancer.2 Measurement of two markers allows identification of prostate cancer patients who have an elevation of PAP but not of PSA, and thus help monitoring the course of disease and response to treatment. PAP is more specific than PSA and less false-positives are seen due to benign prostatic hyperplasia. |
| Footnotes | | - Gutman AB and Gutman EB, “An “Acid” Phosphatase Occurring in the Serum of Patients With Metastasizing Carcinoma of the Prostate Gland,” J Clin Invest, 1938, 17(4):473-8.
- Powell P, Neal D, Gibb I, et al, “Immunologically Measured Serum Markers and Their Role in the Management of Prostate Cancer,” Eur Urol, 1988, 15(1-2):48-53
|
| References | | Killian CS, Emrich LJ, Vargas FP, et al, “Relative Reliability of Five Serially Measured Markers for Prognosis of Progression in Prostate Cancer,” J Natl Cancer Inst, 1986, 76(2):179-85. |
|